Pharma Marketletter articles from February 2004

Pharma Marketletter archives from February 2004

Parexel FY2004 2nd-qtr profits rocket.(Brief Article)
February 2, 2004... For the three months ended December 31, 2003, US biopharmaceutical outsourcing group Parexel International reported consolidated service revenue was $131.0 million, a year-over-year increase of 7.1%. Operating income in the second quarter...

Teva prices $1 billion debenture offering; closes Sicor deal.(Brief Article)
February 2, 2004... Israel-headquartered generics company Teva Pharmaceutical Industries has announced that its Teva Pharmaceutical Finance II, a special purpose finance subsidiary, has priced its offering of $400 million in aggregate principal amount of 0.50%...

US court denies Biogen Idec's motion against Corixa's Bexxar patent.(Brief Article)
February 2, 2004... Corixa has said that the US District Court, Southern District of California, has vacated its October 14, 2003 grant of Biogen Idec's motion for summary judgment in which Bexxar (tositumomab) US Patent Nos 5,595,721; 6,015,542; 6,090,365 and...

Genaera closed $20M equity placement.(Brief Article)
February 2, 2004... US biopharmaceutical firm Genaera Corp says it has closed the sale to four institutional investors in a registered direct offering of 4,950,500 shares of its common stock at a purchase price of $4.04 per share, for aggregate gross proceeds of...

Bumper 4th-qtr/2003 sales at Pfizer, but acquisition costs drag on earnings.(Brief Article)
February 2, 2004... The acquisition of Pharmacia early last year by Pfizer, to create the world's largest pharmaceutical company, has certainly boosted the latter's turnover, but has taken a hefty toll on its earnings, with fourth-quarter 2003 net income profits...

Charges pull Wyeth earnings down 79%.(Brief Article)
February 2, 2004... US pharmaceutical major Wyeth reported a 14% rise in fourth-quarter 2003 revenues at $4.33 billion. However, due to special charges of $639.9 million for manufacturing restructuring and related asset impairments, as well as the cost of debt...

Japanese pharma must build strong R&D capability to survive, says Datamonitor.
February 2, 2004... New research from UK-based market analysts Datamonitor has revealed how the building of strong, in-house, R&D capabilities will be central to Japanese pharmaceutical companies' strategies for survival. However, it says, improving R&D...

Velcade on track for EU approval.(Millennium)(Brief Article)
February 2, 2004... The European Medicines Evaluation Agency's Committee for Proprietary Medicinal Products has issued a positive opinion to recommend approval of Millennium's Velcade (bortezomib). The agent is indicated for the treatment of patients with multiple...

Yamanouchi's Vesicare cleared in Netherlands.(Brief Article)
February 2, 2004... Japan's Yamanouchi has obtained marketing authorization in the Netherlands for use of its Vesicare (solifenacin succinate; YM905) in the treatment of over-active bladder. The Netherlands will act as the reference member state for the European...

OSI/Genentech/Roche's Tarceva filed in USA.(Brief Article)
February 2, 2004... A rolling submission of a New Drug Application with the US Food and Drug Administration, for the use of Tarceva (erlotinib) in the treatment of patients with incurable stage IIIB/IV non-small cell lung cancer who have failed standard therapy...

FDA to fast-track VaxGen's anthrax vacc.(Food and Drug Administration)(Brief Article)
February 2, 2004... The US Food and Drug Administration has granted fast-track status to VaxGen for its anthrax vaccine rPA102. The product is being developed under two contracts valued at more than $100 million from a division of the US National Institutes of...

B-MS and Iconix signs chemogenomics deal.(Brief Article)
February 2, 2004... USA-based Iconix Pharmaceuticals has entered into a research and license agreement with drug major Bristol-Myers Squibb in the field of chemogenomics. Under the terms of the deal, B-MS will access Iconix's DrugMatrix chemogenomics system and...

AEterna unit and Solvay enter collaboration.(Brief Article)
February 2, 2004... Canada's AEterna Laboratories says that its 100%-owned German subsidiary Zentaris GmbH and Solvay Pharmaceuticals BV of Belgium have entered into an extensive collaboration agreement. Based on the agreement, Solvay and Zentaris will jointly...

Cellular Genomics raises $22.3 million.(Nick Colangelo, Douglas Reed)(Brief Article)
February 2, 2004... Cellular Genomics, a US chemical genetics based drug discovery and development company, says that it has raised $22.3 million in the initial close of a Series C private equity financing. This Series C round is being led by Lilly BioVentures,...

Strong sales boost Amgen profit.
February 2, 2004... Shares of leading US biotechnology firm Amgen rose from $61.47 to $61.95 in after-hours trading on January 22, when it reported that fourth-quarter product sales rose 38% to $2.2 billion, resulting in adjusted earnings per share of $0.46,...

BioFocus trading update.(Brief Article)
February 2, 2004... UK collaborative drug discovery company BioFocus has announced a trading update for the 12 months ended 31 December 2003, saying it expects turnover and profit before amortization of goodwill and exceptional items to be within the range of...

Kowa and Nikken to co-promote olmesartan medoxomil.(Brief Article)
February 2, 2004... Japanese firms Kowa and Nikken Chemicals have reached an agreement to co-promote olmesartan medoxmil, a new hypertension drug, for which Sankyo has currently filed manufacturing approval, reports JCN Network. Once approved, the drug will be...

Daiwa Yakuhin to be acquired by Alfresa.(Brief Article)
February 2, 2004... Alfresa Holdings has announced that its consolidated subsidiary Fukujin will acquire the majority share of Japanese pharmaceutical wholesaler Daiwa Yakuhin on April 1, reports JCN Network Capitalized at 60 million yen ($607,900), Daiwa is...

InterMune's Actimmune fails in trial.(Brief Article)(Product/Service Evaluation)
February 2, 2004... InterMune of the USA has reported disappointing results from a Phase II trial evaluating its Actimmune (interferon gamma-1b) as a potential treatment for advanced liver fibrosis, or cirrhosis, caused by the hepatitis C virus in patients who...

Positive results for AVANT's cholera vacc.(Brief Article)
February 2, 2004... Positive preliminary findings from the adult portion of a Phase II trial of AVANT Immunotherapeutics' cholera vaccine, CholeraGarde, have been released. In the ongoing study, being conducted in Bangladesh, vaccination of a single-dose of...

Xoma's topical acne therapy enters Ph II.(Brief Article)(Product/Service Evaluation)
February 2, 2004... USA-based Xoma has initiated a Phase II trial of its XMP.629 peptide, which is under evaluation as a potential topical treatment for acne. The randomized, double-blind, placebo-controlled, dose-ranging study will evaluate the safety and...

Aventis rejects Sanofi-Synthelabo's $60 billion hostile bid.(financial markets analysis, mergers)
February 2, 2004... Following a week of rumors, French drugmaker Sanofi-Synthelabo launched a hostile takeover bid for its much larger rival, the Franco-German Aventis group, valuing the latter at about 47.8 billion euros ($60.1 billion; Marketletter January 26)....

California jury exonerates Novartis in two Phenylpropanolamine cases.(Brief Article)
February 2, 2004... A Los Angeles jury late yesterday rejected Linda Lutz and Pearl O'Neill's claims that Triaminicin and Tavist D (respectively), which contained the over-the-counter decongestant phenylpropanolamine, were unsafe products with inadequate warnings....

First named-patient sales of Protherics' Voraxaze.(Brief Article)
February 2, 2004... UK biopharmaceuticals company Protherics has announced its first named-patient sales in Europe of Voraxaze (carboxypeptidase G2), its treatment for patients at risk of kidney damage from methotrexate toxicity. In Europe, medical practitioners...

Cypress licenses Collegium's milnacipran.(Brief Article)
February 2, 2004... Cypress Bioscience of the USA says it has exercised its option to license the patent portfolio on novel reformulations and new analogs of milnacipran developed by Collegium under the companies' reformulation and new product agreement entered...

EU Commission, EMEA view the path to 2005's pharma regulatory "big bang".
February 2, 2004... In advance of the Council of the European Union's formal approval of the EU pharmaceutical legislation package, expected by the end of the first week in February, the European Commission has identified four areas for "reflection," in order to...

Intron slump, charges lead to S-P loss.
February 2, 2004... In line with earlier warnings, US drug major Schering-Plough has posted a fourth-quarter 2003 loss, as a result of lower sales of some leading products and costs of $229 million relating to voluntary employee terminations ($179 million) and...

Schering AG gets EU approval for Zevalin.
February 2, 2004... Germany's Schering AG says that it has gained marketing approval for Zevalin (ibritumomab tiuxetan) from the European Commission. Zevalin is a radioimmunotherapy treatment approved for use in adult patients with rituximab-elapsed or refactory...

Novartis increases stake in Roche; 2003 results strengthen global position.
February 2, 2004... Swiss drug giant Novartis has increased its holding in smaller rival Roche Holdings from 32.7% to 33.3%. This new level of ownership is just a hair's breadth away from the level at which it is required to make a takeover bid under Swiss law,...

French pharma queries govt health moves.(Brief Article)
February 2, 2004... The French pharmaceutical industry organization, the LEEM, has warned that the health service and funding reforms proposed by the government will lead to the "strategic disengagement of France" from therapeutic progress. The 300 or so...

Bulgarian Health Fund Rx supply moves.(prescription drugs rules)(Brief Article)
February 2, 2004... Bulgaria's National Health Insurance Fund must now apply the Public Procurement Act to obtain supplies of all fully or partly reimbursed drugs, reports the Sofia Echo. Official bodies including the Audit Office had recommended that the Fund...

Michigan: five bills to act on drug prices.
February 2, 2004... A five-bill package of legislation introduced by Republicans in the House of Representatives of the US state of Michigan seeks to allow consumers to pay the same low prices for long-term prescriptions at local pharmacies and mail-order...

Biotech firms "to boost cancer drug level".
February 2, 2004... Biotechnology firms will intensify their efforts to develop a growing number of cancer therapies and market them faster by speeding up development times, forecasts the Center for the Study of Drug Development at Tufts University, USA. ...

Wisconsin Gov warns over Canadian drugs.(Jim Doyle launches web site)(Brief Article)
February 2, 2004... The web site which Jim Doyle, Governor of the US state of Wisconsin, pledged to set up to help residents buy prescription drugs from Canada (Marketletters passim) has now been launched, but contains no links to Canadian pharmacies. A statement...

Nymox to advance NX-1207 to Ph II.(drug trial for the treatment of benign prostatic hyperplasia, Phase II trials)(Brief Article)
February 2, 2004... US firm Nymox Pharmaceutical Corp has revealed that it has concluded the first two Phase I and Phase I/II US trials of NX-1207, a potential new treatment for benign prostatic hyperplasia. The agent was shown to have a good safety profile and...

Merck KGaA/Kos' Niaspan cleared in EU.(European Union procedures)(Brief Article)
February 2, 2004... Germany's Merck KGaA and Kos Pharmaceuticals of the USA have reported that Niaspan, an extended-release formulation of niacin, has successfully completed the European Union's Mutual Recognition Procedure. The agent is indicated for use as an...

FDA OKs expanded use of Provigil.(United States. Food and Drug Administration's approval)(Brief Article)
February 2, 2004... The US Food and Drug Administration has approved the use of Cephalon's narcolepsy drug Provigil (modafinil) to improve wakefulness in patients with excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome and shift work...

US NIH staff payments probe gets underway.(National Institutes of Health)
February 2, 2004... A full review of all outside projects for US government medical researchers has been ordered and, so far, it has turned up no proof that patients have been harmed or any firm has benefited from undue influence over grant proposals or other...

US FDA to educate about OTC painkillers.
February 2, 2004... The US Food and Drug Administration has launched an advertising campaign aimed at alerting consumers to the dangers of over-the-counter painkillers. The FDA's main focus is on acetaminophen, which can poison the liver. The FDA says about...

STAR study confirms safety and efficacy of Abbott's Humira as RA therapy.(Safety Trial of Adalimumab In Rheumatoid Arthritis)
February 2, 2004... Data published in the Journal of Rheumatology has demonstrated that Abbott Laboratories' Humira (adalimumab), when given in conjunction with standard antirheumatic therapy, is a safe and effective therapeutic option in patients with active...

Sankyo's Mevalotin retains number one spot in Japan.(Sankyo Pharma's market share)(Brief Article)
February 2, 2004... Based on semi-annual results for the fiscal year ending March 2004, Sankyo's hyperlipidemic Mevalotin (pravastatin) has retained its number one position on the Japanese pharmaceutical market. Despite the drug's domestic patent expiring last...

More reactions to Sanofi's hostile bid for Aventis.
February 2, 2004... Not only Aventis is against the unsolicited, $60 billion takeover bid for it from French rival Sanofi-Synthelabo (see page 3); analysts are also perplexed. Lehman Brothers' team says it "continues to struggle with the strategic rationale of...

Discovery that genes may raise panic could lead to new therapies.(Brief Article)
February 2, 2004... A new finding, combined with evidence from recent animal studies, suggests that genes might increase the risk of panic disorder by coding for decreased expression of specific receptor molecules, reports the January issue of the US Journal of...

Merck & Co 4th-qtr in line with estimates; net income down 23%.
February 2, 2004... As a result of charges and lower product sales, US drug major Merck & Co has reported a 23% decline in fourth-quarter 2003 net income, which fell to $1.39 billion, or $0.62 per share. However, this was in line with Thomson First Call's...

Altana reports record results for 2003: profits rise 10% and sales increase 5%.(Brief Article)
February 2, 2004... Germany's Altana has announced strong financial results for 2003, with continued solid growth in all areas. Nikolaus Schweickhart, Altana's chairman, said that the company "successfully sustained its long-term forward growth throughout 2003....

Crucell announces positive 2003 results.(Brief Article)
February 2, 2004... Dutch biotechnology firm Crucell has reported positive 2003 results, reflecting its successful transition to a product-focused company. Revenues in 2003 were down to 7.4 million euros ($9.3 million) from 9.6 million euros in 2002, not including...

Vernalis reports solid interim growth.(Brief Article)
February 2, 2004... UK-based Vernalis, which merged with British Biotech last year (Marketletter October 6, 2003) has announced positive interim results for the half year ended October 31, 2003, following two successful mergers during the period. The company...

Cell Genesys sees increased losses.(Brief Article)
February 2, 2004... US firm Cell Genesys has reported a net loss for the quarter ended December 31, 2003, of $17.3 million, or $0.43 per share and of $56.6 million, or $1.48 per share for the full year. This compares with a net loss of $12.3 million and $27.3...

Northfield to raise $15 million.(Northfield Laboratories Inc)
February 2, 2004... US blood-product specialist Northfield Laboratories says it has received commitments to buy $15 million of its common stock in a registered direct offering. Under the terms of the transaction, Northfield will sell around 2.6 million shares at...

Dendreon prices $130.7M stock offering.(Dendreon Corp)(Brief Article)
February 2, 2004... US biotechnology company Dendreon has announced the pricing of its public offering of 10,250,000 shares of common stock at a price of $12.75 per share. The gross proceeds of the offering will be approximately $130.7 million and the underwriters...

AmerisourceBergen to buy MedSelect for $13.5M cash.(Brief Article)
February 2, 2004... AmerisourceBergen says it has signed a definitive agreement to purchase MedSelect, a privately-held provider of automated medication and supply dispensing cabinets for $13.4 million in cash, including assumed debt. The purchase price will be...

German govt intervenes in Sanofi/Aventis fight.(Brief Article)
February 2, 2004... Germany's Federal Economics Minister, Wolfgang Clement, has launched a government intervention in the controversial hostile takeover battle for Aventis (see also pages 3 and 27). The Minister, apparently responding on behalf of the Berlin...

New US Cialis ad to debut at Super Bowl.(Brief Article)
February 2, 2004... Lilly ICOS will debut a 60-second television ad for its new erectile dysfunction drug Cialis (tadalafil) during the US Super Bowl telecast on February 1. Lilly ICOS began airing 15-second awareness spots for ED during the National Football...

FDA concludes Alpharma inspection.(United States. Food and Drug Administration, Alpharma Inc)(Brief Article)
February 2, 2004... Specialty pharmaceutical company Alpharma says that the US Food and Drug Administration has recently completed an inspection at its manufacturing facility in Elizabeth, New Jersey. Following this review, the FDA notified the company regarding...

NeoRx gets payment from Boston Sci.(Brief Article)
February 2, 2004... Cancer therapeutics specialist NeoRx Corp says that it has received a $500,000 payment from fellow US firm Boston Scientific. The payment relates to an agreement under which NeoRx sold and transferred to Boston Scientific certain of its assets...

Tokyo pharma stocks - week to Jan 26.(pharmaceutical)
February 2, 2004... Tokyo saw a retreat in the week to January 26, due to profit-taking on recent gains of a broad range of issues. The Nikkei 225 lost 0.6%, to close at slightly below the psychologically important 11,000 mark, while the Topix index inched down...

Promising new data for GenVec's TNFerade.(tumor necrosis factor alfa)(Brief Article)
February 2, 2004... US biopharmaceutical firm GenVec has released positive new findings for its lead oncology product candidate, TNFerade (tumor necrosis factor alfa), at the ASCO Gastrointestinal Cancers Symposium held in San Francisco, USA. The data...

Actelion's target price bumped up.
February 2, 2004... Switzerland-based Actelion's share price target has been raised by Lehman Brothers to 160 Swiss francs from 130 francs, largely based on an increase in the Tracleer (bosentan) peak sales forecast, to $550 million from $460 million. Analysts are...

Chiesi reports positive results for 2003.(Brief Article)
February 2, 2004... Italy's prescription pharmaceuticals-focused Chiesi Group has reported strong financial results for 2003, ending the year with a substantial increase in revenues. The company achieved net sales of 476 million euros ($600 million) representing a...

Elan gets extra $70 million in deals.(Elan Corporation PLC)(Brief Article)
February 2, 2004... Dublin, Ireland-based Elan Corp has announced four transactions that will collectively realize additional revenues to the company of approximately $70 million. The transactions include: the sale of the company's office property in San...

US state AG sues for Rx "overcharging".(Attorney General)
February 2, 2004... Mike Beebe, Attorney General of the US state of Arkansas, has filed suit against four drugmakers, claiming they illegally misreported drug pricing information to boost profits and their products' market shares. Warrick Pharmaceuticals,...

US "Prairie" Rx drug-buying pilot proposal.(Brief Article)
February 2, 2004... Byron Dorgan, the Democrat Senator for the US state of North Dakota, has proposed a pilot project allowing pharmacists in his state to buy Food and Drug Administration-approved prescription drugs from licensed pharmacists in Canada, saving...

US FDA draft plan on investigational Rx data.(Brief Article)
February 2, 2004... A new US Food and Drug Administration draft guidance, designed to make further information on the use of investigational drugs more readily available, was posted in the Federal Register on January 27, with a 60-day comment period. Part of...

Biogenerics: conference.(Brief Article)
February 2, 2004... Generic biopharmaceuticals' huge impact on the drug industry will be addressed at a conference in Washington DC, USA, on March 25-26. To obtain further details, contact Jon Liong at SRI, e-mail: jliong@srinstitute.com.

Vertex/GSK's Lexiva shown to be promising new HIV therapy; NEAT study findings.(Vertex Pharmaceuticals Inc.)(GlaxoSmithKline AB)
February 2, 2004... Final 48-week results from the NEAT trial, published in the January issue of the Journal of Acquired Immune Deficiency Syndrome, have confirmed the safety and efficacy of GlaxoSmithKline/Vertex Pharmaceuticals' protease inhibitor, Lexiva...

Tanabe licenses Genelabs' lupus drug.(Brief Article)
February 2, 2004... USA-based Genelabs has signed a collaboration and license agreement with Japan's Tanabe Seiyaku for its prasterone (Prestara; Anastar; GL701), an investigational drug for the treatment of systemic lupus erythematosus. Under the terms of...

IVAX on track for new use of Paxene.(Brief Article)
February 2, 2004... IVAX of the USA has received a positive opinion from the European Union's Committee for Proprietary Medicinal Products recommending extending the indications for its proprietary injectable paclitaxel (Paxene) to include treatment of metastatic...

South African HIV/AIDS group slams ARV delay.(antiretroviral drugs )(Brief Article)
February 2, 2004... South Africa's Treatment Action Campaign, an influential lobby group for HIV/AIDS treatment and care, has condemned the fact that, while the government agreed last November that people with the virus should be treated with antiretroviral drugs...

South Korea aims for six new drugs by 2013.(Brief Article)
February 2, 2004... Government measures aimed at strengthening the South Korean biotechnology industry will include the planned development of at least six new drug products by 2013, the Ministry of Health and Welfare has announced. The program calls for...

Singapore raises drug production in 2003.(Brief Article)
February 2, 2004... Production of pharmaceuticals in Singapore in 2003 was 9.3% up on 2002, reports Statistics Singapore, adding that, in comparison, overall production in the country's manufacturing industry was 2.8% higher, year-on-year.

Zimbabwean govt accused over ARV.(antiretroviral drug)(Brief Article)
February 2, 2004... HIV/AIDS patient groups have accused the Medicines Control Authority of Zimbabwe of banning the entry into the country of the antiretroviral drug Nevilast (lamivudine, nevirapine and stavudine), manufactured by Hetero Drugs of Hyderabad, India,...

South African health care price in Dec 2003.(Brief Article)
February 2, 2004... In December 2003, the consumer price of health care in South Africa was 0.6% higher than in November and up 7.9% over December 2002, according to Statistics South Africa. In comparison, the monthly and annual rises in the country's consumer...

Wyeth names Gary Stiles exec VP/chief medical officer.(Brief Article)
February 2, 2004... Gary Stiles has joined Wyeth Pharmaceuticals as executive vice president and chief medical officer, responsible for the US group's clinical R&D organization. Dr Stiles joins from the Duke University Health System, where he held a...

Berna Biotech 2003 sales rise 35%.(Brief Article)
February 2, 2004... Swiss biotechnology vaccines group Berna Biotech was able to increase gross sales in 2003 35% over the previous year to 270 million Swiss francs ($214.7 million). Turnover of hepatitis B and pediatric vaccines rose 29% and sales of the core...

Abbott Labs names James White director of Washington DC office.(Brief Article)
February 2, 2004... US health care major Abbott Laboratories has announced the expansion of its Washington DC staff with the appointment of James White as director, federal government affairs. He was formerly legislative director for US House Energy and Commerce...

Novo Nordisk expands French insulin production capacity.(Brief Article)
February 2, 2004... Danish drugmaker Novo Nordisk is to invest 128 million euros ($159.6 million) in the expansion of its insulin production facilities in the French city of Chartres. The investment is one of the largest to be made by the firm outside Denmark, and...

Aventis confirms five deaths in Japan associated with Arava.(Brief Article)
February 2, 2004... Five Japanese rheumatoid arthritis patients treated with Franco-German firm Aventis' Arava (leflunomide) have died of pneumonia in the four months since the drug became available there. The company's Japanese subsidiary also said that 11 other...

Sirna and Lilly enter RNAi collaboration.(Brief Article)
February 2, 2004... Sirna Therapeutics has entered into a collaboration with drug major Eli Lilly to develop novel RNA-interference therapeutics. During the 18-month alliance, the two companies will jointly evaluate Sirna's proprietary modified small interfering...

ProSkelia's PSK 3471 enters Ph II trials.(Brief Article)
February 2, 2004... ProSkelia, an independent European biopharmaceutical firm focused on bone and hormone disorders, has reported the initiation of Phase IIa clinical studies for PSK 3471. The agent is a new-generation selective-estrogen receptor modulator which...

Pfizer looking to expand use of sildenafil.(Brief Article)
February 2, 2004... The European Commission has granted Orphan Medicinal Product designation to sildenafil citrate, the active ingredient in Pfizer's blockbuster erectile dysfunction therapy Viagra, for the treatment of pulmonary arterial hypertension and chronic...

FDA requires more time to review Vicuron's antifungal agent.(Vicuron Pharmaceuticals)(Brief Article)
February 2, 2004... Vicuron Pharmaceuticals of the USA says that it has received notification from the US Food and Drug Administration that the agency now expects to complete its review of the New Drug Application for the firm's anidulafungin on May 25,...

GPC Biotech extends license for MorphoSys' antibodies.(Brief Article)
February 2, 2004... GPC Biotech has extended its exclusive license for fellow German company MorphoSys' HuCAL antibodies directed against an MHC class II target molecule. No financial details of the deal were disclosed. The collaboration between the two firms...

Crucell nointed Ronald Brus as CEO.(Dinko Valerio has stepped down )(Brief Article)
February 2, 2004... Dutch biotechnology firm Crucell NV has nominated Ronald Brus as its chief executive, replacing co-founder Dinko Valerio who has stepped down as part of a planned management transition.

France's LEEM names Bayer chief Jean-Philippe Milon to board.(Les Entreprise du Medicament (LEEM))(Brief Article)
February 2, 2004... Jean-Philippe Milon, president of the board of Bayer's French company Bayer Sante, has been co-opted onto the board of the drug industry body Les Entreprise du Medicament, LEEM, in place of Jean-Noel Treilles. Mr Milon became president of the...